FLINDERS UNIVERSITY

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1966-01-01

Employees: 1K

Market Cap: -

Website: http://www.flinders.edu.au

Clinical Trials

Reboxetine for Sleep Apnoea After ENT Surgery

Phase 2

Recruiting

Conditions: Sleep Apnea, Obstructive

Interventions: Drug: Reboxetine 4 MG Oral Tablet
Drug: Placebo

First Posted Date: 2023-08-07

Last Posted Date: 2024-10-03

Lead Sponsor: Flinders University

Target Recruit Count: 20

Registration Number: NCT05978505

Locations: 🇦🇺
Flinders, Private and Public Hospitals and Flinders University, Bedford Park, South Australia, Australia

BAY2586116 Nasal Spray and OSA Severity

Phase 1

Completed

Conditions: Sleep Apnea, Obstructive

Interventions: Drug: Placebo
Drug: BAY2586116

First Posted Date: 2022-09-02

Last Posted Date: 2023-02-15

Lead Sponsor: Flinders University

Target Recruit Count: 10

Registration Number: NCT05527457

Locations: 🇦🇺
Flinders University, Bedford Park, South Australia, Australia

Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors

Conditions: Myocarditis
Myocardial Injury
Immune Checkpoint Inhibitors
Cardiotoxicity

Interventions: Drug: Immune Checkpoint Inhibitors

First Posted Date: 2022-04-27

Last Posted Date: 2022-04-27

Lead Sponsor: Flinders University

Target Recruit Count: 40

Registration Number: NCT05349058

Locations: 🇦🇺
Flinders Medical Centre, Adelaide, South Australia, Australia

Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea

Phase 2

Completed

Conditions: Sleep Apnea, Obstructive

Interventions: Drug: Placebo
Drug: Quetiapine 50 MG

First Posted Date: 2022-03-31

Last Posted Date: 2023-07-06

Lead Sponsor: Flinders University

Target Recruit Count: 15

Registration Number: NCT05303935

Locations: 🇦🇺
Adelaide Institute for Sleep Health, Adelaide, South Australia, Australia

Role of Perhexiline in Hypertrophic Cardiomyopathy

Phase 2

Conditions: Hypertrophic Cardiomyopathy

Interventions: Other: Placebo
Drug: Perhexiline

First Posted Date: 2020-06-11

Last Posted Date: 2021-03-11

Lead Sponsor: Flinders University

Target Recruit Count: 60

Registration Number: NCT04426578

Locations: 🇦🇺
Flinders Medical Centre, Adelaide, South Australia, Australia

Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction

Phase 3

Withdrawn

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: Sacubitril-Valsartan

First Posted Date: 2019-10-16

Last Posted Date: 2021-08-30

Lead Sponsor: Flinders University

Registration Number: NCT04128891

Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy

Not Applicable

Not yet recruiting

Conditions: Fibrosis Myocardial
Dilated Cardiomyopathy
Left Ventricular Systolic Dysfunction

Interventions: Device: ICD
Device: ILR

First Posted Date: 2019-06-21

Last Posted Date: 2019-06-21

Lead Sponsor: Flinders University

Target Recruit Count: 1880

Registration Number: NCT03993730

Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis
Stiffness, Aortic
Endothelial Dysfunction
Cardiovascular Risk Factor

Interventions: Drug: Other DMARDs
Drug: Methotrexate
Drug: Sulfasalazine

First Posted Date: 2017-08-18

Last Posted Date: 2022-07-27

Lead Sponsor: Flinders University

Target Recruit Count: 124

Registration Number: NCT03254589

Locations: 🇦🇺
Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia

Breathlessness Exertion and Morphine Sulphate

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Dyspnea

Interventions: Drug: Placebo
Drug: Plus placebo laxative
Drug: Plus laxative (Docusate with senna)
Drug: Morphine Sulfate
Device: FitBit charge HR (Accelerometer)

First Posted Date: 2016-03-28

Last Posted Date: 2020-02-11

Lead Sponsor: Flinders University

Target Recruit Count: 171

Registration Number: NCT02720822

Locations: 🇦🇺
Clare Holland House, Canberra, Australian Capital Territory, Australia
🇦🇺
Barwon Health McKellar Centre, Geelong, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia

and more 12 locations

Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease

Phase 3

Withdrawn

Conditions: Chronic Obstructive Pulmonary Disease
Dyspnea

Interventions: Drug: Placebo
Drug: Morphine sulfate

First Posted Date: 2015-05-27

Last Posted Date: 2016-01-12

Lead Sponsor: Flinders University

Registration Number: NCT02455362

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy